Skip to main content
MANE $124.39 -0.38%
MANE logo
MANE · Veradermics, Inc
Track MANE — free
$124.39 -0.47 (-0.38%) At close · Nov 19
Market Cap
$5.25B
Shares
42.20M
Volume · Nov 19 293.74K Avg daily vol (3M) 739.62K
All webcasts

Conference · 2026-11-19

Veradermics, Inc (MANE) November 19, 2026 Conference Transcript

Concluded Nov 19, 2026 Audio replay
Nov 19, 2026 24:56 1 turns
Period
2026-11-19
Runtime
24:56
Sources
2 artifacts

Transcript & audio

24:56 Audio

All right, good. Good morning, everyone. Thank you for coming and being here bright and early on Thursday at the Jeffrey's London Conference. I'm Reid Waldman. I'm co-founder and CEO of Veridermix, board-certified dermatologist by background, and I'm very excited to talk to you about Veridermix and how we aim to bring forward a new treatment for the 80 million people with pattern hair loss in the U.S. And today there are really three things I want you to take away from the conversation. One is going to be a focus on the Phase III clinical data that we have generated to date in 2026 across both male Phase III placebo-controlled studies and across extension data from our first male Phase III study. The second is that we believe, based on market research generated to date, that there's a potential not only to take share from the existing RX market, but to grow the RX market in pattern hair loss through the introduction of a new therapy with the potential to meet the needs of both patients and physicians. And then finally, number three, is I'd like to talk to you all about our upcoming phase three trial in female pattern hair loss, the first ever phase three study for an oral treatment for female pattern hair loss in the United States. Again, here's our forward-looking statements disclosure. You can find more information on the investor section of our website. Again, we are developing VDPHL01, the first minoxidil extended-release tablet, and the premise is very straightforward. Minoxidil is validated biology for the treatment of hair loss in that it's approved in its topical format for both males and females with pattern hair loss. It is also used off-label as an oral blood pressure medication, and the challenge with that blood pressure medication is exactly what you would expect. Spikes quickly in the plasma, majority has gone within two hours, almost all of it within four hours, and those spikes drive the cardiac effects of the drug. They are not necessary, nor are they conducive to hair growth, and they do not provide consistent and durable exposures at the follicle throughout the day. So the question that we asked at Veridermics is why is the best tool in the dermatologist toolkit a 40-year-old blood pressure medication that no one's revisited, and we set out to optimize it to maximize hair growth and minimize cardiac risk, specifically to raise the hair growth threshold by enabling the delivery of more minoxidil for longer to drive fast results with greater consistency This is a product that has been associated with 5-alpha reductase inhibitors. Additionally, this is an oral format, which is the format clearly preferred by patients. And this is a product that is now characterized by more than 1,000 patients with a placebo-controlled data in male pattern hair loss. Again, we're talking about pattern hair loss or androgenetic alopecia, which is the single most prevalent chronic dermatologic condition in America, affecting 80 million people. That makes it ten times more prevalent than psoriasis, two times more prevalent than psoriasis and atopic dermatitis combined. And despite that prevalence, it's an area that's been starved for innovation. There have been no new oral therapies for males in nearly 30 years. There has never been an oral therapy for female pattern hair loss, and we aim to change that with the development of VDPH-L01. As mentioned, the premise here is very straightforward. We believe that there is essentially a 10x delta between the plasma concentration at which minoxidil will grow hair and the plasma concentration at which it has cardiac effects. And our goal, through an extended-release tablet, is to provide consistent and durable exposures of the drug Between those two thresholds to drive hair growth while minimizing cardiac effects. Importantly, and I think this is something a lot of people miss, minoxidil itself does not grow hair. It's sulfate metabolite, minoxidil sulfate does. And minoxidil sulfate can be produced within the outer root sheath of the hair. And the challenge with this Sult1A1 sulfotransferase is that it's capacity limited, meaning it can saturate with spikes in plasma concentration, And it's time-dependent, meaning it takes time to sulfate the minoxidil. And so if you think about that immediate release blood pressure medication with a quick onset, quick offset, it can saturate metabolism and give insufficient time, whereas with more consistent and durable exposures throughout the day, we believe we can potentially drive the bioactivation of minoxidil and drive further hair growth. And to date, the phase 3 data that we've generated in male pattern hair loss, we believe supports that the pharmacokinetic optimization that we intended to undertake Translates into clinical benefit in patients. Specifically, if you look at our co-primary endpoints on both male Phase III studies, which is the totality of all placebo-controlled data we intend to generate in males, we show a high degree of statistical and clinical significance. With that efficacy profile, we also maintain a safety and tolerability profile that is conducive to an aesthetic condition like pattern hair loss. And finally, our most recent data, which we toplined last Monday, study 302 Part B, which is long-term 12-month data, demonstrated not only that at month two, we show robust increase in target area hair count, but that we see maintenance or deepening of effect at the month 12 period of time. All in, we believe that these help address the top unmet needs that keep patients from seeking treatment with prescription drugs for their pattern hair loss today. Again, we're going to spend some time talking about the Phase III profile and then putting it into context from a market opportunity perspective. To date, we have completed placebo-controlled data from Study 302 and Study 304, our male Phase III studies. Each of these studies enrolled more than 500 subjects at a total of 89 sites across the United States, and they enrolled males who are age 18 to 65. We started with a six-month placebo-controlled period during which patients were randomized to receive either VDPHL01, eight and a half milligrams once daily, twice daily, or placebo. After that six-month placebo-controlled period and the evaluation of the primary endpoints, We then, at a treatment extension period, during which those originally randomized to active continued on the treatment group to which they were originally randomized, those originally randomized to placebo crossed over to either randomized to once-daily or twice-daily VDPHL01. Importantly, we have two co-primary endpoints in these studies, target area hair count and a patient-reported outcome. The target area hair count is a measurement of the number of hairs that one has greater than 30 microns, or what we call non-vellous hairs in a given square centimeter. The patient-reported outcome is a subject's evaluation of their hair coverage change or it's a way in which the patient is able to tell us do they have an improvement in the visible coverage of their hair. And as we look at the data across these two male phase three studies on the first co-primary endpoint of target area hair count, we see increases in the QD and BID group that are statistically significant over placebo and that are highly consistent between these two studies showing, you know, as shown here. And importantly, I think this is something a lot of people potentially missed last Monday, we also have shown a very clear time course of improvement that starts with month two, where we see a fast onset of hair growth. As you can see here at that month two, or, you know, often thought of as like a week eight time point, we see an increase in the once daily group of 28 hairs per square centimeter, an increase in the twice daily group of 39 or 35.9 hairs per square centimeter. And we believe that this rapid onset of hair growth is very important because when we talk to patients, when we talk to physicians, one of the core unmet needs in this therapeutic area is that treatments take too long and patients get discouraged. And so if we can bring, you know, this early sign of encouragement with these hair counts that we see at month two here, it has the potential to help keep people engaged in treatment over time. Importantly, one of the things that we saw in this study that I think was surprising to many is that we had a maintenance to deepening of effect over time, you know, showing our largest reported hair count in the Phase III program to date at month 12 of 43.9. Importantly, these objective and quantifiable changes on the non-bellus hair count also translated into clinically meaningful benefit on the patient-reported outcome with about half of all patients in the once daily group, approximately two-thirds of patients in the twice daily group reporting that they were improved or much improved in their hair coverage. And when we look at, oh, and when we look at, and that's sustained out to month 12, and when we look at the bar of any improvement on hair coverage, I think we see what we believe to be the most important piece of data out of the Phase 3 program. And the reason I say that this is the most important piece of data is that, as mentioned, our goal is to not only take share of the existing RX market, but to grow the RX market like what we've seen with the GLP-1s and obesity or with Viagra in erectile dysfunction. And the reason that we believe there is the potential to do that is based on, you know, the visible hair growth that is noted in these trials, because when you think about a category like obesity, what changed and activated patients into the market was a change in the efficacy of the treatments, right? There is a critical number of pounds per week that, when lost, encouraged people to go and enter the therapeutic landscape. So similarly here, what is it about this data that gives us confidence that it meets the needs of patients? Well, when we work on the PRO, there are two things that we discover. One, what matters to patients. And the primary thing that we believe to be important is visible hair coverage, which I think is probably no surprise to anyone. And number two, how much hair coverage is clinically meaningful. And in our Phase III program, more than 80% of subjects that participated in this part of Study 302 said that any improvement in their hair coverage would be clinically meaningful to them. And as you can see here, more than 80 percent of subjects on a blended basis achieved that level of improvement. And importantly, while not shown here, that level of improvement was consistent with what investigators saw on the investigator global assessment. As a dermatologist, what gives me confidence in that is that if you think about how these visits go, I'm going to ask a patient, how is your hair coverage? And here, more than 80 percent of the time, they're going to say it's improving. And then I'm going to examine them, and based on the Investigator Global, it's very highly likely that we have concordant findings, and that feels like a recipe for success in this category. That efficacy was then matched with a safety intolerability profile that positions VDPHL01 to be a treatment option in pattern hair loss. Specifically, we saw no treatment-related SAEs, no adverse events of special interest of cardiac origin, so no pericardial effusion, pleural effusion, heart failure, angina. Overall rates were tolerable, were primarily mild in nature, primarily self-resolving, and occurred at low to mid-single-digit rates. And we saw no clinically significant changes in vital signs or ECGs and a lack of observed post-treatment initiation shedding. Importantly, when we look at two adverse events that we did see, peripheral edema and hypertrichosis, we see that these rates occurred, again, at low to mid-single-digit rates, and the discontinuation rates were rather low. In fact, if you look at edema discontinuation across studies, we see that less than 1% of subjects discontinued related to peripheral edema, and similarly, that only one subject out of more than 800 treated subjects discontinued for hypertrichosis. The other thing that I want to flag to you is the column on the far right, which is our new data that we released last Monday, were related to the BDPH-L01 continued group in Part B of Study 302. So these are the patients that were originally randomized to active that stayed on active for a total of 12 months of treatment. And what's shown in that column is that second six months of treatment. What you can see, and as was our expectation, there are no new cases of edema, and we had no adverse event-related study discontinuations in that second half of the study in the continued group, and only a mild uptick in hypertrichosis, supporting that early tolerability findings seem to translate over time. All in, we are very confident in the ability of the Phase III profile to meet the needs of both patients and physicians and to give physicians confidence that they can achieve the outcomes their patients are looking for, namely that they can achieve meaningful, visible improvement in a high percentage of patients on a time course that is predictable with fast onset at month two that maintains or is durable, maintains or deepens out to month 12, All while maintaining a safety and tolerability profile that is conducive to this indication in a format that is simple to prescribe, simple to manage, and simple to take, and that is now well characterized by more than 1,000 patients of placebo-controlled data in a male Phase III program, and that has the potential to be the first ever FDA-approved oral treatment for both male and female pattern hair loss. Now, we're going to transition to talking about how this aligns with the market opportunity, and as I mentioned up top, you know, our goal is not only to take existing share of the RX market, but potentially with the introduction of this therapy to grow the RX market by activating patients that are OTC or non-treaters, like what we've seen with weight loss and erectile dysfunction, and we think there are a lot of corollaries between those markets. Similarly, this is a high-prevalence condition in which there have been no approvals in males in almost 30 years for oral treatments, never an approval in females for an oral treatment, where there is significant latent demand, and that latent demand is highlighted by domination of the OTC treatment with more than 10 million OTC users, and in a world where the GLP-1s have paved the road to patient access vis-a-vis emerging channels like telehealth and the direct-to-patient market. Now, importantly, this market in particular, you know, meets through similar types of profile to erectile dysfunction and weight loss, and that it's a deeply dissatisfied market with only 9% of patients reporting satisfaction with existing treatment options and up to half of patients actively seeking new treatment. And the reason for this are that treatments today, they're slow. They're inconsistent. When they do work, they have, you know, variable levels of hair growth, and even with that, you know, level of efficacy, patients are forced to choose between tolerability issues like erectile dysfunction or decreased libido or messy topical application twice daily for life, and all in, a lack of data-supported options, minimal FDA-approved options. When we think about this market and think about the 80 million people in this market, we segment it based on treatment-seeking status. So as you can see here, from a brick-and-mortar perspective, there are nearly 3 million patients that are on Rx. There are more than 10 million patients that are using OTC. And then we say a little over 7 million patients are showing that they're digitally intent to treat. And what we mean by that is that we were able to obtain, using the V database, search information, digital information for roughly 96% of American households. And in doing so, we looked for people who were showing five or more signs of intent to treat, meaning they're Googling or they're on YouTube and they're looking in these different manners, because that's been validated in the obesity market to suggest that these are people that are actively seeking treatment for their hair loss. And what we see is that all in, there are more than 20 million people that are actively in these high-priority market segments. Now, that's not to say that we couldn't convert the other 60, but that these are the high-priority segments that we think about as we move towards And importantly, as I mentioned, one of the things that has been almost as exciting as the clinical data that we've generated over the last year is the market opportunity research data that we've generated with our actual phase three profile. And over the last several months, we have done work with both patients and physicians to answer really four core questions. Can VDPHL01 own share of existing RX patients? Can VDPHL01 grow the market via OTC users and nontreaters? Can VDPHL01 become a go-to for high-volume treaters? And can VDPHL01 broaden the prescriber base? And the answer, based on the market opportunity research conducted to date, is yes across the board. And we'll talk about this in greater detail via our prescriber research in both high-volume treaters and in those we call hesitant prescribers, meaning that they're seeing the patients but they're not writing a lot of prescriptions, as well as in our patient research, in patients that are currently engaged in Rx, as well as those that are on OTC or not treating. We started in the study 302A readout showing our phase 2-3 profile to engaged patients, and we saw that 85% of patients that are currently on an Rx are very or extremely likely to talk to their doctor about BDPHL1 due primarily to its hair growth results and the FDA approval potential of the product, and that they see an urgency in doing so with approximately 79% talking to their doctor or anticipating talking to their doctor within three months. And this is driven by 95% of patients saying that they believe the VDPHL01 profile to be positively differentiated versus currently available options. This data shown here supports the ability to potentially take share of the existing RX market in the pattern hair loss. We then have gone to patients who are OTC users and non-treaters. Before we talk about all that they've told us about VDPHL01, I want to talk about what they told us about themselves. In the OTC market, and this is male subjects, males tell us they're spending $76 on average a month, with 30% spending $100 or more. So this is a market where people are actively spending, and with that spending, only 15% of OTC treaters are highly satisfied with their current treatment. Importantly, one of the barriers to people being on a prescription treatment today is that they haven't heard of them. In fact, you know, a quarter to a third of patients in the OTC bucket had never heard of common prescription treatments that are utilized for pattern hair loss today. We then went to those who are not currently treating, and I think one of the big questions many people have is, if someone is not currently treating their hair loss, is that because they're not interested in treating their hair loss? What we heard is that 82% of these patients are interested in or have looked into treatment, And that 57% of them say their hair is very or extremely important to their self-confidence. Like the OTC patients, the barriers that they just haven't heard of common RX treatments. Now, importantly, we then want to understand how could VDPH-L01 change their treatment disposition to potentially grow the Rx market and grow our potential opportunity beyond today's Rx market. We hear that 79% are open to considering an Rx treatment if their doctor recommends it, and that efficacy for 53% is the single most important factor in treatment. When we show them the VDPH-L01 profile, it hits that most important, right? 87%, say, has greater overall efficacy. They then talk about having milder side effects, no hormonal sexual side effects, quicker results, etc. All in, we believe that VDPHL01 can activate men that are not on Rx today and that, importantly, that preference to VDPHL01 withstands an understanding of a premium pricing profile. Eighty-three percent of these men said they were likely to talk to a doctor. That's driven by a view that it's positively differentiated, and they're willing to pay for it. And I think a lot of people go, well, why is the preference for VDPHL01 able to sustain premium pricing? Will patients tell us it's the amount of hair growth, the percentage of patients improving, the amount of hair growth on the front of the head in particular, a recommendation potential from a doctor, or that it's an oral pill? And here you can see, again, patients' own words as to why they see value in paying for VDPHL01. We're now going to talk about the work we've done with physicians, starting with high-volume treaters. So this is, right, the core prescriber base today. We've said that for oral minoxidil, that roughly 80% of prescriptions are written by only 11,000 prescribers in the U.S., and that roughly 30% are written by under 1,000 prescribers. When we go to these core prescribers, we see a high percentage view this as being positively differentiated, that they show a high likelihood to prescribe, And that they would put 52% or the majority of their existing patients on VDPH-L01 with an urgency with 72% anticipating adoption within three months of launch. And that's driven by VDPH-L01's ability to address their unmet needs of more FDA-approved treatments, greater overall efficacy, and an option without hormonal or sexual side effects. We then went out to those who are what we call hesitant prescribers. Because one of the things that we've seen, you know, in the obesity market is that, you know, GLP-1s used to be predominantly written by endocrinologists. Now even some of my dermatology colleagues write them. And so we wanted to understand what would it take to get people that are seeing hair loss but not actively using prescription treatment to enter and engage as prescribers in this treatment landscape. And so we went out to these hesitant prescribers. They include some people in the derm landscape. Primarily NPs, PAs, also primary care physicians. And we see that, you know, for this set of people, you know, 64% of their patients are not being treated with RX. In fact, their dominant recommendation today is topical minoxidil or Rogaine. When exposed to the VDPHL01 profile, they expect their use of RX to double, and 86% of these people who are hesitant prescribers anticipate prescribing VDPHL01 in its first 12 months, with more than half of their patients anticipate to be on VDPHL01 in the first 12 months. And I think as you think about how people will access treatment, it's very important that not everyone has to get into one of the existing core prescriber high-volume treaters, that the current hesitant prescriber who see these patients are open to this profile. And, again, when you look at why that is, you can see the barriers they identify that keep them from using Rx today and how the VDPHL1 profile can potentially address those barriers and how that results in positive differentiation and, again, a preference that withstands a premium price. All in, this clinical profile that we talked about, combined with a potential comprehensive go-to-market commercialization strategy, we believe gives the potential not only to drive substantial existing Rx market share, but to potentially grow the market and capture share of that growth. Final comment on clinical data before we make brief commentary on study 306, our phase 3 trial of female pattern hair loss, is to walk through patients at 12 months from study 302. These patients are stratified based on their patient-reported outcome response, with this showing patients with a plus-one response, which is a reminder, more than 80% of subjects on a blended basis in the trial achieved at least this much hair growth. We then go to those who are improved, and we see an even greater degree of hair growth in both the vertex and the frontal scalp. And we go to those who are much improved, and we see substantive hair regrowth with almost renormalization in these individuals over the 12 months of treatment. Again, as we mentioned, these two male studies represent the totality of our placebo-controlled data. We have now transitioned to study 306, our Phase III trial for female pattern hair loss. This study by design looks very similar to the male studies with more than 550 subjects at 72 sites across the U.S., and importantly, we study the same co-primary endpoints with the same randomization or similar randomization schedule in this. And we believe this is a high-confidence readout based on what we've already seen in our Phase II profile in female pattern hair loss to date, where we saw a profile that looks similar to what was seen with men with that rapid onset of effect at early as month two with increases in target area hair count, a consistency on the patient-reported outcome, a tolerable profile, and again, the convenience of oral administration. And in the female patient in particular, I cannot overstate how important we think that oral administration over topical is, given that messy topicals can be very difficult in individuals with long hair. All in, we've been very pleased with the clinical data that has been generated to date in 2026. We've been almost equally as pleased with the commercial market research that supports a potential durable commercial opportunity for VDPHL01. And we look forward to toplining the first ever phase three trial for an oral treatment for female pattern hair loss in the first half of 2027. Thank you. Thank you.

Full-screen source Call document